Marker Therapeutics (MRKR)
NASDAQ:MRKR
Want to see MRKR full AI Analyst Report?
Top Page
Marker Therapeutics
(NASDAQ:MRKR)
Select Model
Select Model
Rating:43Neutral
Price Target:
$1.50
▼(-9.64% Downside)
Action:ReiteratedDate:05/05/26
The score is primarily held down by weak financial performance (persistent losses and ongoing cash burn). Technical signals are neutral-to-soft with no strong trend confirmation, while valuation is constrained by a negative P/E. The recent authorization to materially increase shares adds financing flexibility but introduces meaningful dilution risk.
Positive Factors
Differentiated cell‑therapy platform
Marker’s multi‑tumor antigen T‑cell platform is a technology‑led competitive asset that aims to reduce tumor‑escape risk. A validated multi‑antigen approach offers durable differentiation across indications, improves likelihood of clinical value per asset, and supports partnership or licensing opportunities over time.
Negative Factors
Persistent cash burn
Operating and free cash flow remain negative year after year, indicating structural cash burn to fund R&D and operations. This creates a durable need for external financing, raises dilution risk, and limits the firm's ability to self‑fund late‑stage trials or scale manufacturing without dilutive or costly capital raises.
Read all positive and negative factors
Positive Factors
Negative Factors
Differentiated cell‑therapy platform
Marker’s multi‑tumor antigen T‑cell platform is a technology‑led competitive asset that aims to reduce tumor‑escape risk. A validated multi‑antigen approach offers durable differentiation across indications, improves likelihood of clinical value per asset, and supports partnership or licensing opportunities over time.
Read all positive factors
Marker Therapeutics (MRKR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$26.01M
Dividend YieldN/A
Average Volume (3M)146.50K
Price to Earnings (P/E)―
Beta (1Y)1.73
Revenue Growth-46.19%
EPS Growth23.89%
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.91
Shares Outstanding16,673,126
10 Day Avg. Volume209,118
30 Day Avg. Volume146,500
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)<0.01
Price to Sales (P/S)6.43
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-617.76K
Enterprise Value/Revenue-4.53M
Enterprise Value/Gross Profit3.30M
Enterprise Value/Ebitda1.97M
Forecast
1Y Price Target
$9.00Price Target Upside442.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.23
Revenue Forecast (FY)$2.68M
Marker Therapeutics Business Overview & Revenue Model
Company Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumo...
How the Company Makes Money
null...
Marker Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.55M | 6.59M | 3.31M | 3.51M | 1.24M |
| Gross Profit | 0.00 | -6.88M | -7.11M | -8.45M | -1.92M |
| EBITDA | -12.44M | -11.12M | -11.79M | -17.00M | -38.72M |
| Net Income | -12.16M | -10.73M | -8.24M | -29.93M | -41.88M |
Balance Sheet | |||||
| Total Assets | 19.07T | 22.02M | 17.13M | 34.42M | 68.14M |
| Cash, Cash Equivalents and Short-Term Investments | 16.07T | 19.19M | 15.11M | 11.78M | 42.35M |
| Total Debt | 0.00 | 0.00 | 0.00 | 7.62M | 11.87M |
| Total Liabilities | 2.27T | 3.46M | 3.07M | 14.82M | 24.15M |
| Stockholders Equity | 16.80T | 18.56M | 14.05M | 19.60M | 43.99M |
Cash Flow | |||||
| Free Cash Flow | -12.01T | -10.91M | -16.44M | -26.97M | -30.41M |
| Operating Cash Flow | -12.01T | -10.91M | -16.44M | -26.97M | -27.28M |
| Investing Cash Flow | 0.00 | 0.00 | 18.66M | -4.95M | -3.13M |
| Financing Cash Flow | 9.86T | 14.99M | 1.11M | 202.13K | 52.56M |
Marker Therapeutics Technical Analysis
Positive
1.66
Price Trends
1.45
Positive
1.51
Positive
1.33
Positive
Market Momentum
0.06
Negative
61.04
Neutral
64.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRKR, the sentiment is Positive. The current price of 1.66 is above the 20-day moving average (MA) of 1.45, above the 50-day MA of 1.45, and above the 200-day MA of 1.33, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 61.04 is Neutral, neither overbought nor oversold. The STOCH value of 64.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MRKR.
Marker Therapeutics Risk Analysis
Marker Therapeutics disclosed 55 risk factors in its most recent earnings report. Marker Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Marker Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $8.87M | -1.00 | -71.27% | ― | -21.69% | -194.45% | |
48 Neutral | $19.77M | -1.15 | -112.05% | ― | ― | 99.89% | |
47 Neutral | $13.23M | 0.63 | ― | ― | ― | 76.57% | |
46 Neutral | $57.11M | -5.32 | -71.26% | ― | -20.00% | 62.69% | |
45 Neutral | $26.71M | -3.48 | -88.89% | ― | -100.00% | 21.87% | |
43 Neutral | $26.01M | -3.35 | >-0.01% | ― | -46.19% | 23.89% |
* Healthcare Sector Average
MRKR
Marker Therapeutics
1.56
0.33
26.83%
IBIO
Ibio
1.58
0.61
62.05%
MBRX
Moleculin Biotech
2.48
-23.52
-90.46%
ABVC
ABVC BioPharma
1.05
-0.07
-6.25%
ADXN
Addex Therapeutics
6.93
-1.52
-17.99%
ALLR
Allarity Therapeutics
1.25
0.19
17.92%
Marker Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Marker Therapeutics Shareholders Approve Governance and Capital Changes
Positive
May 4, 2026
At its May 1, 2026 annual meeting, Marker Therapeutics’ shareholders re-elected all five director nominees and approved, on an advisory basis, executive compensation, while also ratifying CBIZ CPAs P.C. as the independent auditor for the 202...
Regulatory Filings and ComplianceShareholder Meetings
Marker Therapeutics Sets Date for 2026 Annual Meeting
Neutral
Feb 9, 2026
On February 9, 2026, Marker Therapeutics, Inc. announced that its Board of Directors had set May 1, 2026 as the date for the company’s 2026 Annual Meeting of Stockholders, a move that advances the meeting more than 30 days from the prior yea...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.